Regulatory Paradox and Market Restructuring: Unintended Effects of the Two-Invoice System on Pharmaceutical Prices and Their Micro-Mechanisms
This paper investigates the regulatory paradox where China's Two-Invoice System, intended to lower drug prices, inadvertently caused ex-factory prices to rise by forcing manufacturers to internalize distribution and marketing costs through vertical integration or outsourcing, thereby reshaping the industry's organizational structure and creating new regulatory blind spots.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The Big Picture: A "Two-Receipt" Rule That Backfired
Imagine the pharmaceutical industry (drug companies) as a giant factory that makes medicine. Before 2017, getting that medicine from the factory to a hospital was like a game of "pass the parcel" with too many people involved.
The Old Way (The Multi-Receipt System):
The factory sold the medicine to a middleman (Distributor A), who sold it to Distributor B, who sold it to Distributor C, who finally sold it to the hospital.
- The Problem: Every time the medicine changed hands, a new "receipt" (invoice) was created, and every middleman added a hidden fee or a markup. It was like a game of telephone where the message got distorted and expensive by the time it reached the end. This created a lot of "gray money" (bribes and kickbacks) to keep the chain moving.
The Government's Fix (The Two-Invoice System):
In 2017, the Chinese government said, "Stop the game of pass-the-parcel." They introduced a rule: Only two receipts are allowed.
- One from the Factory to the Distributor.
- One from the Distributor to the Hospital.
The goal was to cut out the middlemen, stop the hidden fees, and make medicine cheaper for patients.
The Paradox (The Surprise Result):
The government expected drug prices to go down. Instead, something strange happened: The price the factory charges (the "ex-factory price") went UP.
The researchers call this a "Regulatory Paradox." The rule worked on paper (fewer receipts), but in reality, the cost didn't disappear; it just moved.
How Did This Happen? (The "Cost Migration" Analogy)
Think of the drug distribution process like a restaurant delivery service.
Before the Rule:
The restaurant (Factory) made the food and handed it to a delivery guy (Distributor). The delivery guy had to pay a "tip" to the restaurant manager to get the order, and then he added his own fee to get the food to the customer. The restaurant didn't care about the delivery; they just sold the food cheaply to the delivery guy.
After the Rule:
The government said, "No more middlemen! The restaurant must deliver the food directly to the customer, or use only one official delivery partner."
The Restaurant's Reaction:
The restaurant couldn't just stop delivering. They still needed to:
- Persuade the customer to order.
- Build relationships with the customer.
- Handle the logistics of getting the food there.
Since they couldn't use the old middlemen anymore, the restaurant had to do two things:
- Hire their own delivery team (Vertical Integration).
- Pay a specialized "consulting firm" to handle the sales pitch (Outsourcing to CSOs).
The Result:
The cost of hiring that delivery team or paying the consulting firm didn't vanish. The restaurant simply added that cost to the price of the food before they handed it over.
- Old Price: Factory sells to distributor for $10. Distributor sells to hospital for $50. (Factory revenue = $10).
- New Price: Factory sells to distributor for $45 (because they now have to pay for the sales team). Distributor sells to hospital for $50. (Factory revenue = $45).
The final price to the patient stayed roughly the same, but the Factory's invoice jumped from $10 to $45. The "gray costs" (bribes/markups) were now hidden inside the factory's official "Sales and Marketing" budget instead of being hidden in the middlemen's pockets.
What the Data Actually Showed
The researchers looked at the financial records of Chinese drug companies from 2014 to 2022 and found:
- Revenue Went Up, Profit Stayed Flat: Drug companies reported much higher sales numbers (because their "ex-factory price" went up), but their actual profit didn't increase. Why? Because they spent all that extra money on sales staff, marketing conferences, and consulting fees.
- The "Sales Team" Grew: Companies hired more salespeople or paid more to outside agencies to do the selling work that distributors used to do.
- Who Got Hurt the Most?
- Small Companies: They couldn't afford to build their own sales teams, so they had to pay expensive outside agencies, eating into their profits.
- Generic Drug Makers: Companies making common, non-specialty drugs had to fight harder to sell, so they spent more on marketing.
- Innovative Companies: Companies making unique, patented drugs were less affected because their products were already in high demand.
- The Ecosystem Changed:
- Traditional "wholesalers" (the old middlemen) started disappearing or shrinking.
- A new type of business exploded: Medical Consulting Firms (CSOs). These are companies that don't move boxes of medicine; they just provide "marketing services" and "consulting" to help drug companies sell their products. This created a new "blind spot" for regulators.
The Bottom Line
The "Two-Invoice System" successfully cleaned up the paperwork (fewer receipts), but it failed to clean up the economics.
The functions that the middlemen used to perform (selling, marketing, relationship building) didn't disappear. They just moved upstream to the drug factories. The factories absorbed these costs, raised their official prices to cover them, and passed the burden on.
The Lesson: You can't just regulate the number of steps in a process. If the work still needs to be done, the market will find a new way to do it, often shifting the costs to a different part of the system. In this case, the "gray market" costs became "white market" marketing expenses, and the price of medicine didn't actually drop for the patient.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.